Pushing New Boundaries in Tricuspid Valve Regurgitation Treatment

Publication Date: 13 December, 2021

Source: Headline Daily

Tricuspid valve regurgitation is a condition where the tricuspid valve is not able to close completely, causing a backflow of blood from the right ventricle to the right atrium.

If a patient’s condition is mild, he or she may not experience symptoms and treatment is not needed. However, if the patient is experiencing fatigue, shortness of breath with light activity, pulsing in the neck, leg swelling, fluttering discomfort in the neck or swelling of the abdomen, then this warrants treatments. Severe tricuspid valve regurgitation can lead to fatal heart failure and abnormal heart rhythm.

In the past, severe tricuspid regurgitation could be treated with mechanical heart valves, which may come with an increased risk of blood clots and the necessity of long-term use of blood thinners. Today, biologic valves, the newer generation valves, made from pig or cow tissue typically address the issue of clotting. There are many transcatheter devices to treat tricuspid valve regurgitation, among which, a new technology has emerged to treat severe tricuspid valve regurgitation without touching the valve, which is particularly suitable for patients at high risk for surgical procedure.

TricValve^® is a bicaval transcatheter tricuspid valve implantation system, which includes two bicaval valves, one to be implanted in the superior vena cava and the other in the inferior vena cava. The TricValve transcatheter bicaval valves are already pre-mounted into the delivery system, with a dry tissue valve technology that is ready for use without further processing needed inside the cardiac catheterization lab. TricValve aims to reduce blood backflow, alleviate congestion, promote remodelling of the heart and increase heart output. Most patients will experience reduction of symptoms and the procedure time is also relatively shorter compared to alternative procedures.

OrbusNeich^® P&F, our joint venture with an European partner has the exclusive right to register and distribute certain heart valve products, including TricValve, in the Greater China Area, Japan, Australia, New Zealand, South Korea, Malaysia and Singapore and manufacture heart valve products in China. TricValve is OrbusNeich P&F’s first heart valve device to commercialise and has recently been granted with the CE Mark along with a Breakthrough Device designation from the U.S. FDA.

It is always our mission to give patients better quality of life and we will continue to strive for excellence.